Chikungunya Fever


Article Author:
Jafet Ojeda Rodriguez


Article Editor:
J Walker, III


Editors In Chief:
Alexandra Caley
Sameh Boktor


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
2/19/2019 12:41:37 PM

Introduction

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus that belongs to the family Togaviridae transmitted by Aedes mosquitoes. The virus is known for causing an acute febrile illness, rash, and arthralgia known as Chikungunya fever followed by potentially chronic and debilitating arthritic symptoms that may last for months or years.[1] Historically, CHIKV was found mainly in Africa and Asia, initially isolated in the Makonde Plateau in Tanzania in 1952.[2] The name Chikungunya is derived from a Makonde phrase meaning, "that which bends up." The worst outbreak reported occurred in the Reunion Island in 2005-2006 affecting nearly 35% of the population.[3] Since 2005, cases of Chikungunya fever have spread mainly in tropical and sub-tropical regions finally reaching the Americas via the Caribbean island of St. Martin in 2013.[4] Today, CHIKV is widespread worldwide and is a global public health concern.

Etiology

The primary vectors for CHIKV are Aedes aegypti and Ae. albopictus (Asian Tiger mosquito). These mosquitoes have biological characteristics that provide effective invasiveness, vector competence, and vectorial capacity that sets the tone for the global manifestation of Chikungunya fever.[5] Invasiveness is highlighted by the species' preference for human blood and its historically-proven ability to establish outside of their native range. Vector competence is determined by the species' physiological characteristics that allow for transmission, such as virus ingestion with blood meal and subsequent infection of the mosquitoes’ salivary glands.[6] Most importantly, vector capacity determines outbreak potential and is mainly influenced by intrinsic (mosquito infection barriers and genetics) and extrinsic (environmental issues) factors. Vector density in relation to the host, the probability that vector feeds on a host in one day, vector survivability, and extrinsic incubation period are all vector competence factors that determine infectivity directly.[7]

Ae. aegypti has been established in the U.S. for more than 300 years while Ae. albopictus has been present since 1985 with different vector characteristics making global expansion of the disease possible. Specifically, CHIKV was found to have adapted to Ae. albopictus fairly recently during the Indian Ocean outbreak in 2005-06 when it acquired a mutation in its E1 membrane protein that allowed it to infest the urban mosquito vector.[8] In general, the threat to public health posed by Ae. aegypti and Ae. albopictus mosquitoes is a function of their focused feeding on and association with humans along with the ability of the human host and mosquito vector to travel.[9]

Epidemiology

CHIKV was first discovered in Tanzania in 1952, has since spread effectively reaching the Americas in 2013, Florida on July 2014, and severely affecting various Caribbean, Central, and South American countries after that.[10] Although the CHIKV virus is considered to be endemic in certain parts of West Africa, global distribution has been facilitated by both human and vector travel. Infected travelers import CHIKV into new areas where local Aedes mosquitoes initiate local transmission.[11] Mosquito larvae and egg transport by ships and air traffic has also been described as dissemination means for mosquitoes into naive and suitable environments.[12] Transmission is mostly via mosquito bites, although maternal-fetal and blood product transmission was also described during the Reunion Island outbreaks.[13]

Ae. aegypti and Ae. albopictus are also the vectors responsible for other notable diseases such as Dengue and Zika, causing coinfection in some cases.[14] Given the similarity in clinical presentation and nearly identical geographic distribution, and differentiation of disease has become an issue.

Pathophysiology

CHIKV is known to transmit in 2 cycles: urban and sylvatic. Urban transmission is from human to mosquito to human and is the main source of the current Western Hemisphere epidemic. Sylvatic transmission can be found in Africa and is based on animal to mosquito to human.[15] As mentioned previously, CHIKV was initially transmitted through the vector Ae. aegypti, but incorporation of Ae. albopictus through a mutation in the E1 envelope protein not only increased the fitness of the virus in this species but improved transmissibility to vertebrates.[16][17]

The route of infection used by CHIKV starts after inoculation and infection of human epithelial and endothelial cells, primary fibroblasts, and monocyte-derived macrophages.[18] After an initial immune response and sheltering in the lymph nodes, CHIKV travels through the lymphatic and circulatory system causing significant viremia.[19] Transportation into target organs (muscles, joints, liver, and brain) has been found to be caused by infected monocyte-derived macrophages.[18] Inflammatory reaction mediated by CD8+ (acute), CD4+ T lymphocytes, and pro-inflammatory cytokines are thought to be responsible for the acute symptoms, while a persistent reservoir of infected monocytes in the joints may be responsible for chronic joint disease.[20]

Histopathology

CHIKV is an arthropod-carried pathogen of the genus alphavirus and the family Togaviridae that possesses 3 known genotypes: Asian, West African, and East Central South African.[21] The virus is described as a positive-sense, single-stranded RNA virus, and sensitive to temperatures greater than 58 C.[17]

History and Physical

Chikungunya fever usually presents with the non-specific findings of high-grade fever and myalgia, following a 3 to 7 day incubation period, and lasting around 3 to 5 days. Bilateral symmetrical polyarthralgia ensues 2 to 5 days after the onset of fevers and preferentially involves distal over proximal joints.[22] The hands have been found to be affected the most with some involvement reported to the axial skeleton, knees, and ankles accompanied by intense pain that lasts between one and three weeks.[23] Another common clinical manifestation is a generalized maculopapular rash that usually involves the extremities first and arises 3 days after the fever symptoms.[24] Although rare, vesiculobullous and mucocutaneous lesions have also been reported.[25][26]

Manifestations such as abdominal pain, diarrhea, vomiting, and generalized lymphadenopathy may also be found. Although it is not considered to be a neurotropic virus, it has long been associated with neurologic symptoms, with encephalitis among newborns infected through mother-to-child transmission being the most common.[27] In a 2018 study in Puerto Rico, red eyes, conjunctivitis, and anterior uveitis were frequently found in patients with Chikungunya fever.[28] Other studies have described recurrent retinitis,[29] congenital ocular symptoms,[30] sepsis/septic shock,[31] and renal manifestations.[32]

Evaluation

Chikungunya fever evaluation consists mainly of the clinical findings of fever and polyarthralgia in a person who recently returned from an affected region with an 84% sensitivity, 71% positive predictive value (PPV), and 83% negative predictive value (NPV).[33] However, overlap of endemic and invaded CHIKV and Dengue virus (DENV) areas makes evaluation and differentiation of disease difficult. CHIKV is more likely to cause high fever, severe arthralgia, arthritis, rash, and lymphopenia, while DENV is more likely to cause neutropenia, thrombocytopenia, hemorrhage shock, and death.[34] In light of this, WHO recommends treating everyone for DENV until proven otherwise to improve outcomes. 

Diagnosis of CHIKV can be established or confirmed by detection of viral RNA with serology and/or reverse-transcription polymerase chain reaction (RT-PCR) depending on disease timeframe presentation.[35] RT-PCR is mainly used during acute infection, during the first five days of disease for best results. On the other hand, viral serology using enzyme-linked immunosorbent assay (ELISA) or indirect fluorescent antibody (IFA) is used for detection of anti-chikungunya antibodies IgM (present from five days to several weeks) and IgG (present from two weeks to several years), depending on the stage of disease.[36][37] The CDC and WHO recommend gathering serology for CHIKV, DENV, and Zika virus (ZV) for all patients with suspicious clinical symptoms.[38]

Chikungunya fever is a nationally notifiable condition.

Treatment / Management

Symptomatic relief is the mainstay treatment for Chikungunya fever, including adequate hydration, rest, and pain/fever relief preferably with acetaminophen.[39] WHO discourages the use of aspirin and most nonsteroidal anti-inflammatory drugs (NSAIDs) during the first 48 hours due to the risk of aggravating platelet dysfunction, especially in cases of possible DENV coinfection. Other studies advocate for the efficacy of low-dose corticosteroid drugs for the first 2 months of post-acute disease.[40] Ocular manifestations including anterior and posterior uveitis have been treated with topical steroids and cycloplegics.[41]

Chronic manifestations, including persistent or relapsing-remitting polyarthralgia, polyarthritis, and myalgia, have been found to respond adequately to hydroxychloroquine in combination with corticosteroids or other disease modifying anti-rheumatic drugs (DMARDs).[42][43] Specific antivirals targeting viral replication using siRNAs[44] and virus entry/replication[45] are showing promising results but have not been approved for human use.[46]

Management of CHIKV is based on avoidance of mosquito bites. Use of repellents containing DEET, wearing protective clothing, bed nets, and air-conditioned buildings are great ways to prevent exposure.[47] Furthermore, prevention of mosquito proliferation should be implemented by reduction of peri-domiciliary water puddles.[23] Insecticides have been another means of vector management using four types of drugs: carbamates, organochlorides, organophosphates, and pyrethroids. Nonetheless, insecticide resistance of Ae. aegypti and Ae. albopictus has been of increasing concern.[48] Vaccines are also a hot topic for research and development, but none have yet been approved for patient use.[49]

Differential Diagnosis

Given the non-specific findings of arthralgia, high fever, and rash, the differential diagnosis for the acute and chronic manifestations of Chikungunya fever can be extensive. As mentioned above, DENV and ZK share not only clinical findings but also identical vectors with CHIKV, which prompts serology testing for all 3 viruses when a patient presents with the above symptoms.[38] Other infections that should be considered include:

  • Malaria
  • Yellow fever
  • Leptospirosis
  • Measles
  • Mononucleosis
  • African tick bite fever

Chronic arthralgia caused by Chikungunya fever can be easily confused with other more common causes. Furthermore, worse outcomes and increased morbidity has been demonstrated for patients with underlying joint disease and are super-infected with CHIKV.[50] The differential diagnosis for chronic manifestations includes:

  • Seronegative rheumatoid arthritis
  • Reiter arthritis
  • Rheumatoid arthritis 
  • Hepatitis C
  • Systemic lLupus erythematosus

Prognosis

Despite a low case fatality ratio (CFR), Chikungunya fever is highlighted by a substantial post-chikungunya chronic polyarthralgia, defined as joint pains lasting longer than 6 weeks.[51] A study published in 2018, composed of Aruba CHIKV cases, reported that 26% of all serology-confirmed infected patients presented with post-chikungunya polyarthritis.[52] Another study published in 2018, from 2014 French Guiana, reported post-CHIKV rheumatic or musculoskeletal pain at 3 and 6 months of 40% and 31.3% respectively of all RT-PCR proven cases.[50]

Complications

As mentioned previously, chronic arthritis is the most common and serious complication of Chikungunya fever. Ocular manifestations of disease can include conjunctivitis, optic neuritis, iridocyclitis, episcleritis, retinitis, and uveitis.[53] The most common complications are iridocyclitis and retinitis and have been found to be typically benign and self-limited.[54]

Consultations

Chronic arthritis from Chikungunya fever has emerged as a concern for rheumatologist specialists worldwide due to swelling and recurrent pain that poorly responds to treatment with analgesics, and because it is a debilitating disease that mimics rheumatic arthritis and compromises the quality of life.[55][56]

Deterrence and Patient Education

Chikungunya fever is a virus transmitted to people by mosquitoes found mainly in tropical and sub-tropical environments. Originating from Asia, this disease has caused serious outbreaks in the Western Hemisphere since 2013. The most common symptoms of this disease are high fevers and joint pain, although headaches, muscle pains, and rash may also occur. Risk factors for the disease consist of travel to affected areas or anywhere with mosquitoes and mosquito bites. Treatment consists of rest, adequate hydration, and pain relief with acetaminophen. Prevention is key and is based on protection from mosquito bites with clothing, DEET, and mosquito nets. Given the risk of co-infection with other viruses from the mosquito bite, individuals with these symptoms must seek medical care immediately.

Pearls and Other Issues

  • Chikungunya fever is an arthropod-borne alphavirus from the Togaviridae family endemic to Asia that is transmitted by Aedes aegypti and Aedes albopictus mosquitoes and has caused serious worldwide outbreaks with a preference for tropical and sub-tropical climates.
  • The Aedes mosquito vectors are also responsible for transmitting Dengue virus and Zika virus, so co-infection is possible.
  • Acute clinical manifestations of high fevers, polyarthralgia, and maculopapular rash begin after a 3- to 7-day incubation accompanied by a headache and myalgia. Ocular, neurological, and fetal manifestations have been found in rare instances.
  • Chronic arthritis is the most common and severe complication leading to specialist rheumatologic care.
  • Diagnosis is obtained with the above clinical findings accompanied by a history of recent travel to an affected area or exposure to mosquito bites. Diagnosis confirmation is performed with RT-PCR or viral serology. The CDC recommends that all patients with exposure and symptoms be tested for CHIKV, DENV, and ZK.
  • Supportive care with rest, hydration, and analgesic agents is the mainstay treatment. Aspirin and NSAIDs should be avoided initially for risk of co-infection with DENV. Chronic manifestations can be treated with steroids and disease-modifying anti-rheumatic drugs (DMARDs). No antivirals or vaccines are commonly used.
  • Prevention with avoidance of mosquito bites is paramount. DEET, clothing with coverage, and mosquito nets. Insecticides have been used as a public health measure, but resistance is a factor of increased concern.
  • Chikungunya fever is a reportable disease to the CDC.

Enhancing Healthcare Team Outcomes

Mosquitoes represent the arthropod-vector with the most impact in the world, transmitting diseases from Chikungunya fever to malaria with incalculable morbidity and mortality. Given the lack of specific treatment for most of these diseases, vector control remains the main form of prevention. Insecticide public health campaigns have proven to be effective in the past, but widespread resistance has put a dent on these efforts.[57] (Level V) Another focus of prevention proven in Brazilian studies has been personal protection and individual actions including use of DEET, bed nets, light-colored long-sleeve clothing, and reduction of peri-domiciliary water puddles/reservoirs.[58] (Level I)

When it comes to improving outcomes, the CDC has highlighted the dangers of CHIKV and DENV co-infection and the differences in treatment modalities, important for all healthcare professionals, to avoid Dengue fever-related deaths.[59] A 2018 review highlighted the importance of proper diagnosis (gathering serology DENV, CHIKV, and ZV serology on affected individuals), surveillance, and management to avoid poor prognosis.[60] (Level I)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Chikungunya Fever - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following viruses has been associated with joint manifestations?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following mosquito species is the vector for Chikungunya fever?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 66-year-old female comes with complaints of hands and knee pain accompanied by headache, myalgia, and abdominal pain since five days ago. Vital signs are temperature 102.0 degrees F, pulse 72 bpm, respirations 10/minute, and pulse oximetry 98%. She reports she just returned from vacations at the Florida Keys and has a strong family history of rheumatoid arthritis. What confirmatory diagnostic testing should be performed?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is relatively new mosquito species considered responsible for the Western Hemisphere outbreak of arboviruses including dengue fever, Chikungunya fever, and Zika after escaping its endemic Asia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Chikungunya Fever - References

References

Severe Manifestations of Chikungunya Fever in Children, India, 2016., Sharma PK,Kumar M,Aggarwal GK,Kumar V,Srivastava RD,Sahani A,Goyal R,, Emerging infectious diseases, 2018 Sep     [PubMed]
Morbilliform skin rash with prominent involvement of the palms in Chikungunya fever., Tini ML,Rezza G,, IDCases, 2018     [PubMed]
Clinical profile of dengue fever and coinfection with chikungunya., Singh J,Dinkar A,Singh RG,Siddiqui MS,Sinha N,Singh SK,, Ci ji yi xue za zhi = Tzu-chi medical journal, 2018 Jul-Sep     [PubMed]
Horwood PF,Buchy P, Chikungunya. Revue scientifique et technique (International Office of Epizootics). 2015 Aug     [PubMed]
ROBINSON MC, An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1955 Jan     [PubMed]
Rougeron V,Sam IC,Caron M,Nkoghe D,Leroy E,Roques P, Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Mar     [PubMed]
Fernández-Salas I,Danis-Lozano R,Casas-Martínez M,Ulloa A,Bond JG,Marina CF,Lopez-Ordóñez T,Elizondo-Quiroga A,Torres-Monzón JA,Díaz-González EE, Historical inability to control Aedes aegypti as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral research. 2015 Dec     [PubMed]
Higgs S,Vanlandingham D, Chikungunya virus and its mosquito vectors. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2015 Apr     [PubMed]
Lounibos LP,Kramer LD, Invasiveness of Aedes aegypti and Aedes albopictus and Vectorial Capacity for Chikungunya Virus. The Journal of infectious diseases. 2016 Dec 15     [PubMed]
Kramer LD,Ciota AT, Dissecting vectorial capacity for mosquito-borne viruses. Current opinion in virology. 2015 Dec     [PubMed]
Cunze S,Kochmann J,Koch LK,Klimpel S, Niche conservatism of Aedes albopictus and Aedes aegypti - two mosquito species with different invasion histories. Scientific reports. 2018 May 16     [PubMed]
Weaver SC,Forrester NL, Chikungunya: Evolutionary history and recent epidemic spread. Antiviral research. 2015 Aug     [PubMed]
Renault P,Balleydier E,D'Ortenzio E,Bâville M,Filleul L, Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Medecine et maladies infectieuses. 2012 Mar     [PubMed]
Pialoux G,Gaüzère BA,Jauréguiberry S,Strobel M, Chikungunya, an epidemic arbovirosis. The Lancet. Infectious diseases. 2007 May     [PubMed]
Paupy C,Delatte H,Bagny L,Corbel V,Fontenille D, Aedes albopictus, an arbovirus vector: from the darkness to the light. Microbes and infection. 2009 Dec     [PubMed]
Contopoulos-Ioannidis D,Newman-Lindsay S,Chow C,LaBeaud AD, Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis. PLoS neglected tropical diseases. 2018 Jun     [PubMed]
Singh SK,Unni SK, Chikungunya virus: host pathogen interaction. Reviews in medical virology. 2011 Mar     [PubMed]
Lum FM,Ng LF, Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral research. 2015 Aug     [PubMed]
Ganesan VK,Duan B,Reid SP, Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017 Dec 1     [PubMed]
Sourisseau M,Schilte C,Casartelli N,Trouillet C,Guivel-Benhassine F,Rudnicka D,Sol-Foulon N,Le Roux K,Prevost MC,Fsihi H,Frenkiel MP,Blanchet F,Afonso PV,Ceccaldi PE,Ozden S,Gessain A,Schuffenecker I,Verhasselt B,Zamborlini A,Saïb A,Rey FA,Arenzana-Seisdedos F,Desprès P,Michault A,Albert ML,Schwartz O, Characterization of reemerging chikungunya virus. PLoS pathogens. 2007 Jun     [PubMed]
Kam YW,Ong EK,Rénia L,Tong JC,Ng LF, Immuno-biology of Chikungunya and implications for disease intervention. Microbes and infection. 2009 Dec     [PubMed]
Chow A,Her Z,Ong EK,Chen JM,Dimatatac F,Kwek DJ,Barkham T,Yang H,Rénia L,Leo YS,Ng LF, Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. The Journal of infectious diseases. 2011 Jan 15     [PubMed]
Caglioti C,Lalle E,Castilletti C,Carletti F,Capobianchi MR,Bordi L, Chikungunya virus infection: an overview. The new microbiologica. 2013 Jul     [PubMed]
Hua C,Combe B, Chikungunya Virus-Associated Disease. Current rheumatology reports. 2017 Oct 5     [PubMed]
Runowska M,Majewski D,Niklas K,Puszczewicz M, Chikungunya virus: a rheumatologist's perspective. Clinical and experimental rheumatology. 2018 May-Jun     [PubMed]
Madariaga M,Ticona E,Resurrecion C, Chikungunya: bending over the Americas and the rest of the world. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016 Jan-Feb     [PubMed]
Pakran J,George M,Riyaz N,Arakkal R,George S,Rajan U,Khader A,Thomas S,Abdurahman R,Sasidharanpillai S,Thumbayil L, Purpuric macules with vesiculobullous lesions: a novel manifestation of Chikungunya. International journal of dermatology. 2011 Jan     [PubMed]
Bandyopadhyay D,Ghosh SK, Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. International journal of dermatology. 2008 Nov     [PubMed]
Ulloa-Padilla JP,Dávila PJ,Izquierdo NJ,García-Rodríguez O,Jiménez IZ, Ocular Symptoms and Signs of Chikungunya Fever in Puerto Rico. Puerto Rico health sciences journal. 2018 Jun     [PubMed]
Salceanu SO,Raman V, Recurrent chikungunya retinitis. BMJ case reports. 2018 Aug 27     [PubMed]
Merle H,Donnio A,Jean-Charles A,Guyomarch J,Hage R,Najioullah F,Césaire R,Cabié A, [Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever (French translation of the article)]. Journal francais d'ophtalmologie. 2018 Aug 30     [PubMed]
Rajapakse S,Rodrigo C,Rajapakse A, Atypical manifestations of chikungunya infection. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010 Feb     [PubMed]
Arpino C,Curatolo P,Rezza G, Chikungunya and the nervous system: what we do and do not know. Reviews in medical virology. 2009 May     [PubMed]
Thiberville SD,Moyen N,Dupuis-Maguiraga L,Nougairede A,Gould EA,Roques P,de Lamballerie X, Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral research. 2013 Sep     [PubMed]
Le Coupanec A,Tchankouo-Nguetcheu S,Roux P,Khun H,Huerre M,Morales-Vargas R,Enguehard M,Lavillette D,Missé D,Choumet V, Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes. International journal of molecular sciences. 2017 Aug 4     [PubMed]
Jain J,Nayak K,Tanwar N,Gaind R,Gupta B,Shastri JS,Bhatnagar RK,Kaja MK,Chandele A,Sunil S, Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jul 1     [PubMed]
Panning M,Grywna K,van Esbroeck M,Emmerich P,Drosten C, Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerging infectious diseases. 2008 Mar     [PubMed]
Kumar P,Pok KY,Tan LK,Angela C,Leo YS,Ng LC, Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection. Journal of virological methods. 2014 Sep     [PubMed]
Loconsole D,Metallo A,De Robertis AL,Morea A,Quarto M,Chironna M, Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. Vector borne and zoonotic diseases (Larchmont, N.Y.). 2018 Jun     [PubMed]
Simon F,Javelle E,Cabie A,Bouquillard E,Troisgros O,Gentile G,Leparc-Goffart I,Hoen B,Gandjbakhch F,Rene-Corail P,Franco JM,Caumes E,Combe B,Poiraudeau S,Gane-Troplent F,Djossou F,Schaerverbeke T,Criquet-Hayot A,Carrere P,Malvy D,Gaillard P,Wendling D, French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Medecine et maladies infectieuses. 2015 Jul     [PubMed]
Martí-Carvajal A,Ramon-Pardo P,Javelle E,Simon F,Aldighieri S,Horvath H,Rodriguez-Abreu J,Reveiz L, Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review. PloS one. 2017     [PubMed]
Mahendradas P,Avadhani K,Shetty R, Chikungunya and the eye: a review. Journal of ophthalmic inflammation and infection. 2013 Feb 11     [PubMed]
Sánchez-Duque JA,Orozco-Hernández JP,Rodríguez-Morales AJ, Rheumatic Manifestations in Patients with Chikungunya Infection: Comment on the Article by Arroyo-Ávila and Vilá. Puerto Rico health sciences journal. 2015 Dec     [PubMed]
Ravindran V,Alias G, Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clinical rheumatology. 2017 Jun     [PubMed]
Parashar D,Paingankar MS,Kumar S,Gokhale MD,Sudeep AB,Shinde SB,Arankalle VA, Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS neglected tropical diseases. 2013     [PubMed]
Subudhi BB,Chattopadhyay S,Mishra P,Kumar A, Current Strategies for Inhibition of Chikungunya Infection. Viruses. 2018 May 3     [PubMed]
Oliveira AF,Teixeira RR,Oliveira AS,Souza AP,Silva ML,Paula SO, Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses. Molecules (Basel, Switzerland). 2017 Mar 22     [PubMed]
Audain G,Maher C, Prevention and Control of Worldwide Mosquito-Borne Illnesses: Nurses as Teachers Online journal of issues in nursing. 2017 Jan 31     [PubMed]
Moyes CL,Vontas J,Martins AJ,Ng LC,Koou SY,Dusfour I,Raghavendra K,Pinto J,Corbel V,David JP,Weetman D, Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. PLoS neglected tropical diseases. 2017 Jul     [PubMed]
Schwameis M,Buchtele N,Wadowski PP,Schoergenhofer C,Jilma B, Chikungunya vaccines in development. Human vaccines & immunotherapeutics. 2016 Mar 3     [PubMed]
Bonifay T,Lienne JF,Bagoée C,Santa F,Vesin G,Walter G,Nacher M,Vaserman N,Djossou F,Epelboin L, Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2018 Nov     [PubMed]
Silva JVJ Jr,Ludwig-Begall LF,Oliveira-Filho EF,Oliveira RAS,Durães-Carvalho R,Lopes TRR,Silva DEA,Gil LHVG, A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta tropica. 2018 Dec     [PubMed]
Huits R,De Kort J,Van Den Berg R,Chong L,Tsoumanis A,Eggermont K,Bartholomeeusen K,Ariën KK,Jacobs J,Van Esbroeck M,Bottieau E,Cnops L, Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia. PloS one. 2018     [PubMed]
Martínez-Pulgarín DF,Chowdhury FR,Villamil-Gomez WE,Rodriguez-Morales AJ,Blohm GM,Paniz-Mondolfi AE, Ophthalmologic aspects of chikungunya infection. Travel medicine and infectious disease. 2016 Sep - Oct     [PubMed]
Mahendradas P,Ranganna SK,Shetty R,Balu R,Narayana KM,Babu RB,Shetty BK, Ocular manifestations associated with chikungunya. Ophthalmology. 2008 Feb     [PubMed]
Sharma SK,Jain S, Chikungunya: A rheumatologist's perspective. International journal of rheumatic diseases. 2018 Mar     [PubMed]
Naqqash MN,Gökçe A,Bakhsh A,Salim M, Insecticide resistance and its molecular basis in urban insect pests. Parasitology research. 2016 Apr     [PubMed]
Silva NMD,Teixeira RAG,Cardoso CG,Siqueira Junior JB,Coelho GE,Oliveira ESF, Chikungunya surveillance in Brazil: challenges in the context of Public Health. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2018 Sep 3     [PubMed]
Furuya-Kanamori L,Liang S,Milinovich G,Soares Magalhaes RJ,Clements AC,Hu W,Brasil P,Frentiu FD,Dunning R,Yakob L, Co-distribution and co-infection of chikungunya and dengue viruses. BMC infectious diseases. 2016 Mar 3     [PubMed]
Salam N,Mustafa S,Hafiz A,Chaudhary AA,Deeba F,Parveen S, Global prevalence and distribution of coinfection of malaria, dengue and chikungunya: a systematic review. BMC public health. 2018 Jun 8     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of CNS-Public Community Health. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for CNS-Public Community Health, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in CNS-Public Community Health, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of CNS-Public Community Health. When it is time for the CNS-Public Community Health board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study CNS-Public Community Health.